Halozyme Therapeutics, Inc. $HALO Shares Acquired by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 39.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,013 shares of the biopharmaceutical company’s stock after buying an additional 6,241 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Halozyme Therapeutics were worth $2,430,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Bank of America Corp DE bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at $214,504,000. William Blair Investment Management LLC bought a new stake in shares of Halozyme Therapeutics in the second quarter worth $196,540,000. Congress Asset Management Co. grew its holdings in shares of Halozyme Therapeutics by 85.6% in the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after acquiring an additional 1,052,509 shares during the period. Royal London Asset Management Ltd. grew its holdings in shares of Halozyme Therapeutics by 12.4% in the second quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock worth $141,732,000 after acquiring an additional 200,262 shares during the period. Finally, First Trust Advisors LP increased its position in Halozyme Therapeutics by 46.5% during the first quarter. First Trust Advisors LP now owns 1,482,340 shares of the biopharmaceutical company’s stock valued at $95,804,000 after acquiring an additional 470,558 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Down 0.2%

NASDAQ:HALO opened at $130.91 on Friday. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $134.00. The business has a fifty day moving average price of $113.70 and a 200-day moving average price of $83.45. The firm has a market capitalization of $14.86 billion, a price-to-earnings ratio of 39.08, a price-to-earnings-growth ratio of 0.49 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same period in the previous year, the business earned $1.54 earnings per share. Halozyme Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 8.31 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. TD Cowen upped their price target on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Halozyme Therapeutics from $70.00 to $78.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $99.55.

Insider Activity

In other news, Director Matthew L. Posard sold 18,996 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the sale, the director directly owned 58,839 shares in the company, valued at $6,339,313.86. This trade represents a 24.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $82,482,605.40. This trade represents a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 125,852 shares of company stock valued at $13,538,046 in the last ninety days. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.